Long-term prevention of recurrent hepatitis B virus after liver transplantation

Y. Ilan, A. Eid, R. Tur-Kaspa

Research output: Contribution to journalArticlepeer-review

3 Scopus citations

Abstract

Hepatitis B virus (HBV) reinfection is a major threat to HBV-infected patients undergoing orthotopic liver transplantation. Eleven HBsAg-positive patients with end-stage liver disease underwent liver transplantation. All were treated with high doses of anti-HBs antibodies, initiated first during the anhepatic stage of the operation and continued every 2-8 weeks thereafter according to anti-HBs levels in the serum. Attempts were made to keep anti-HBs levels above 400 IU/ml. Patients were followed for 8-42 months and only one of them had any evidence for recurrence of HBV infection 40 months post-transplantation. We conclude that continuous administration of anti-HBs and maintenance of high levels of anti-HBs in the serum prevent recurrence of HBV infection.

Original languageEnglish
Pages (from-to)469-473
Number of pages5
JournalIsrael Journal of Medical Sciences
Volume31
Issue number8
StatePublished - Aug 1995
Externally publishedYes

Keywords

  • Hepatitis B virus
  • Liver transplantation

Fingerprint

Dive into the research topics of 'Long-term prevention of recurrent hepatitis B virus after liver transplantation'. Together they form a unique fingerprint.

Cite this